Mirati Therapeutics | MRTX - Текущие активы



Текущие активы Изменить Дата
Agios Pharmaceuticals USD 834.84M 107.21M 2026-03
Alnylam Pharmaceuticals USD 4.05B 97.85M 2025-12
Amgen USD 29.06B 1.17B 2025-12
Astellas Pharma JPY 1.42T 19.35B 2026-03
AstraZeneca USD 29.61B 890M 2026-03
Bayer EUR 32.91B 30M 2025-12
BioCryst Pharmaceuticals USD 404.35M 48.66M 2025-12
Bristol-Myers Squibb USD 35.63B 2.41B 2025-09
Eisai JPY 840.88B 50.18B 2025-12
Eli Lilly USD 55.63B 6.44B 2025-12
Exelixis USD 1.44B 41.03M 2025-12
Gilead Sciences USD 19.89B 1.05B 2025-12
GlaxoSmithKline GBP 17.76B 251M 2026-03
Incyte USD 5.48B 460.36M 2026-03
Ionis Pharmaceuticals USD 2.94B 52M 2026-03
J&J USD 59.17B 3.55B 2026-03
Merck USD 47.56B 10.49B 2025-09
Moderna USD 6.54B 54M 2025-12
Nektar Therapeutics USD 266.27M 15.09M 2025-12
Novartis USD 30.46B 2.26B 2025-12
Pfizer USD 46.92B 3.22B 2025-09
Puma Biotechnology USD 143.58M 7M 2025-09
Roche Holding CHF 38.73B 3.03B 2025-12
Sarepta Therapeutics USD 2.54B 184.37M 2025-12
Takeda JPY 3.12T 195.82B 2025-12
Ultragenyx Pharmaceutical USD 643.21M 76.58M 2025-09